EyeD Pharma
- Industry
- Pharmaceuticals
- Founded Year
- 2012
- Headquarters
- Rue Louis Plescia 9, 4102 Seraing, Belgium
- Employee Count
- 50
Key People
- Jean-Michel Foidart - CEO
- Jean-Marie Foidart - CSO
- Jean-Franois Dormal - CFO
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical technology and pharmaceuticals.
The leadership team's extensive experience in medical technology and pharmaceuticals provides a strong foundation for the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: EyeD Pharma addresses significant unmet needs in ophthalmic diseases such as glaucoma and dry eye.
By targeting ophthalmic diseases with substantial unmet needs, EyeD Pharma is well-positioned to make a meaningful impact on patient care and capture significant market share.
- Competition
-
Aspect: Somewhat crowded
Summary: The ophthalmic devices market is competitive, with several established players.
The presence of established competitors in the ophthalmic devices market necessitates strategic differentiation and innovation for EyeD Pharma to successfully penetrate and expand its market presence.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing sustained-release micro-implants involves moderate technical challenges.
While the development of sustained-release micro-implants presents certain technical challenges, they are considered moderate and can be effectively addressed with appropriate expertise and resources.
- Patent
-
Aspect: Strong
Summary: EyeD Pharma has a robust patent portfolio protecting its technologies.
A robust patent portfolio safeguards EyeD Pharma's innovations, offering protection against competitors and enhancing the company's valuation and attractiveness to investors.
- Financing
-
Aspect: Medium
Summary: The company has secured funding from investors like Noshaq and InvestSud.
Although EyeD Pharma has obtained funding from reputable investors, further capital may be required to support scaling operations, clinical trials, and market entry strategies.
- Regulatory
-
Aspect: Pivotal Trial
Summary: EyeD Pharma is in the clinical-stage, progressing through pivotal trials.
Navigating the regulatory landscape, including conducting pivotal trials and obtaining necessary approvals, is a critical step that may involve complexities and potential delays impacting time-to-market.
Opportunity Rollup
- Odds of Success
- 3.9
- Peak Market Share
- 5.2
- Segment CAGR
- 4.3%
- Market Segment
- Ophthalmic Devices
- Market Sub Segment
- Sustained-Release Micro-Implants
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.78 |
| 3 | 1.82 |
| 4 | 3.64 |
| 5 | 5.20 |
Key Takeaway
EyeD Pharma, with its experienced team and focus on unmet ophthalmic needs, holds promise but must navigate a competitive landscape and regulatory challenges to achieve market success.